About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PSTI
- Previous Close: $1.13
- 50 Day Moving Average: $1.23
- 200 Day Moving Average: $1.48
- 52-Week Range: $1.04 - $1.85
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.11
- P/E Growth: 0.00
- Market Cap: $107.59M
- Outstanding Shares: 96,065,000
- Beta: 0.12
- Return on Equity: -75.68%
- Return on Assets: -62.58%
Companies Related to Pluristem Therapeutics:
- Current Ratio: 4.27%
- Quick Ratio: 4.27%
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?
3 brokers have issued twelve-month price objectives for Pluristem Therapeutics' stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Pluristem Therapeutics' share price to reach $4.33 in the next twelve months.
When will Pluristem Therapeutics announce their earnings?
Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 13th 2017.
What are analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (2/15/2017)
Maxim Group analysts commented, "A more comprehensive black box warning added to fluoroquinolone labels. Yesterday, the FDA issued a Drug Safety Communication that it had approved an updated safety label for all fluoroquinolone antibacterial drugs to include an updated Boxed Warning about the risk of disabling and potentially irreversible serious reactions that can occur together. This action by the FDA is a follow-up to a May 12, 2016, drug safety communication requiring the drug labels and Medication Guides for all fluoroquinolones to include a revised Boxed Warnings, which in turn is the result of an Advisory Committee meeting held last November on the safety of this drug class. What appears to be new here is the addition of a statement advising restricted use of fluoroquinolones for patients who lack alternative treatment options for indications, such as uncomplicated urinary tract infection (uUTIs), acute bacterial exacerbations of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS)." (7/27/2016)
Who owns Pluristem Therapeutics stock?
Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.76%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman.
Who bought Pluristem Therapeutics stock? Who is buying Pluristem Therapeutics stock?
Pluristem Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman.
How do I buy Pluristem Therapeutics stock?
Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pluristem Therapeutics stock cost?
One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.12.